Clinical Trial Update: Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant pembrolizumab + ramucirumab for PD-L1 positive stage IB-IIIA non-small cell lung cancer (EAST ENERGY).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Masahiro Tsuboi | Conditions: Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II | Phase 2 | Status: UNKNOWN